Actively Recruiting
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Led by GlaxoSmithKline · Updated on 2026-04-22
420
Participants Needed
114
Research Sites
215 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether Ris-Rez is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving Ris-Rez and the other receiving topotecan.
CONDITIONS
Official Title
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years or older or minimum legal adult age at consent
- Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC)
- Received 1 prior platinum-based systemic therapy with a PD-(L)1 inhibitor for at least 2 cycles and chemotherapy free interval greater than 30 days with documented progression
- Prior tarlatamab treatment in first- or second-line ES-SCLC setting is allowed
- At least 1 target lesion per RECIST 1.1 as determined by investigator
- Capable of giving signed informed consent and complying with study requirements
- Adequate organ function and ECOG performance status of 0 or 1
You will not qualify if you...
- Pathological diagnosis of complex SCLC or transformed SCLC
- Limited stage small cell lung cancer at diagnosis
- Prior therapy with an antibody-drug conjugate (ADC) containing Topoisomerase-1 inhibitor payload or treatments targeting B7-H3
- Known sensitivity or allergy contraindicating study participation
- Severe, uncontrolled or active cardiovascular disorders
- Clinically significant bleeding or bleeding tendency within 1 month prior to first dose
- Known active infectious diseases requiring systemic treatment or known HIV
- Symptomatic brain metastases or untreated progression due to brain metastases, leptomeningeal/brainstem/spinal cord metastases
- Evidence or history of interstitial lung disease or pneumonitis requiring high-dose steroids
- Significant pulmonary disease or respiratory impairment such as uncontrolled asthma, COPD, or restrictive lung disease
- Active Hepatitis B or Hepatitis C
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 114 locations
1
GSK Investigational Site
Mar del Plata, Buenos Aires, Argentina, 7600
Actively Recruiting
2
GSK Investigational Site
Buenos Aires, Argentina, C1426ABP
Actively Recruiting
3
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina, C1012AAR
Actively Recruiting
4
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina, C1426AGE
Actively Recruiting
5
GSK Investigational Site
Rosario, Argentina, S2000 DEJ
Actively Recruiting
6
GSK Investigational Site
Vicente López, Argentina, 1602
Actively Recruiting
7
GSK Investigational Site
Blacktown, New South Wales, Australia, 2148
Actively Recruiting
8
GSK Investigational Site
St Leonards, New South Wales, Australia, 2065
Actively Recruiting
9
GSK Investigational Site
Nedlands, Western Australia, Australia, 6009
Actively Recruiting
10
GSK Investigational Site
Barretos, Brazil, 14784-400
Actively Recruiting
11
GSK Investigational Site
CuritibaPR, Brazil, 80810-050
Actively Recruiting
12
GSK Investigational Site
Florianópolis, Brazil, 88020-210
Actively Recruiting
13
GSK Investigational Site
Porto Alegre, Brazil, 90020-090
Actively Recruiting
14
GSK Investigational Site
Porto Alegre, Brazil, 90610-000
Actively Recruiting
15
GSK Investigational Site
Rio de Janeiro, Brazil, 22250-905
Actively Recruiting
16
GSK Investigational Site
São Paulo, Brazil, 04312903
Actively Recruiting
17
GSK Investigational Site
Pleven, Bulgaria, 5800
Actively Recruiting
18
GSK Investigational Site
Plovdiv, Bulgaria
Actively Recruiting
19
GSK Investigational Site
Rousse, Bulgaria, 7002
Actively Recruiting
20
GSK Investigational Site
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
21
GSK Investigational Site
Toronto, Ontario, Canada, M5G 1Z5
Actively Recruiting
22
GSK Investigational Site
Montreal, Quebec, Canada, H3T 1E2
Actively Recruiting
23
GSK Investigational Site
Montreal, Quebec, Canada, H4J 1C5
Actively Recruiting
24
GSK Investigational Site
Vaasa, Finland, 65130
Actively Recruiting
25
GSK Investigational Site
Boulogne-Billancourt, France, 92100
Actively Recruiting
26
GSK Investigational Site
Grenoble, France, 38043
Actively Recruiting
27
GSK Investigational Site
Saint-Herblain, France, 44805
Actively Recruiting
28
GSK Investigational Site
Karlsruhe, Baden-Wurttemberg, Germany, 76137
Actively Recruiting
29
GSK Investigational Site
Augsburg, Germany, 86156
Actively Recruiting
30
GSK Investigational Site
Esslingen am Neckar, Germany, 73730
Actively Recruiting
31
GSK Investigational Site
Lübeck, Germany, 23562
Actively Recruiting
32
GSK Investigational Site
München, Germany, 81377
Actively Recruiting
33
GSK Investigational Site
Nuremberg, Germany, 90340
Actively Recruiting
34
GSK Investigational Site
Stuttgart, Germany, 70376
Actively Recruiting
35
GSK Investigational Site
Athens, Greece, 115 22
Actively Recruiting
36
GSK Investigational Site
Athens, Greece, 11526
Actively Recruiting
37
GSK Investigational Site
Athens, Greece, 12462
Actively Recruiting
38
GSK Investigational Site
Heraklion Crete, Greece, 71110
Actively Recruiting
39
GSK Investigational Site
Pylaia Thessaloniki, Greece, 570 01
Actively Recruiting
40
GSK Investigational Site
Pylaia Thessaloniki, Greece, 57001
Actively Recruiting
41
GSK Investigational Site
Gyöngyös, Hungary, 3200
Actively Recruiting
42
GSK Investigational Site
Kecskemét, Hungary, 6000
Actively Recruiting
43
GSK Investigational Site
Törökbálint, Hungary, 2045
Actively Recruiting
44
GSK Investigational Site
Dublin, Ireland, D09 V2N0
Actively Recruiting
45
GSK Investigational Site
Jerusalem, Israel, 9112001
Actively Recruiting
46
GSK Investigational Site
Tel Aviv, Israel, 6423906
Actively Recruiting
47
GSK Investigational Site
Bergamo, Italy
Actively Recruiting
48
GSK Investigational Site
Orbassano, Italy, 10043
Actively Recruiting
49
GSK Investigational Site
Pisa, Italy, 57124
Actively Recruiting
50
GSK Investigational Site
Fukuoka, Japan, 812-8582
Actively Recruiting
51
GSK Investigational Site
Hokkaido, Japan, 060-8648
Actively Recruiting
52
GSK Investigational Site
Ishikawa, Japan, 920-8530
Actively Recruiting
53
GSK Investigational Site
Kagoshima, Japan, 890-8520
Actively Recruiting
54
GSK Investigational Site
Kanagawa, Japan, 241-8515
Actively Recruiting
55
GSK Investigational Site
Kanagawa, Japan, 252-0375
Actively Recruiting
56
GSK Investigational Site
Kochi, Japan, 783-8505
Actively Recruiting
57
GSK Investigational Site
Kyoto, Japan, 612-8555
Actively Recruiting
58
GSK Investigational Site
Mie, Japan, 515-8544
Actively Recruiting
59
GSK Investigational Site
Miyagi, Japan, 980-8574
Actively Recruiting
60
GSK Investigational Site
Osaka, Japan, 541-8567
Actively Recruiting
61
GSK Investigational Site
Osaka, Japan, 573-1191
Actively Recruiting
62
GSK Investigational Site
Osaka, Japan, 594-0073
Actively Recruiting
63
GSK Investigational Site
Tokyo, Japan, 113-8603
Actively Recruiting
64
GSK Investigational Site
Tokyo, Japan, 113-8677
Actively Recruiting
65
GSK Investigational Site
Toyama, Japan, 930-8550
Actively Recruiting
66
GSK Investigational Site
Guadalajara, Mexico, 44280
Actively Recruiting
67
GSK Investigational Site
Mexico City, Mexico, 06700
Actively Recruiting
68
GSK Investigational Site
Mexico City, Mexico, 06760
Actively Recruiting
69
GSK Investigational Site
Monterrey, Mexico, 66260
Actively Recruiting
70
GSK Investigational Site
Kielce, Poland, 25-640
Actively Recruiting
71
GSK Investigational Site
Otwock, Poland, 05-400
Actively Recruiting
72
GSK Investigational Site
Poznan, Poland, 60-569
Actively Recruiting
73
GSK Investigational Site
Siedlce, Poland, 08-110
Actively Recruiting
74
GSK Investigational Site
Almada, Portugal, 2805-267
Actively Recruiting
75
GSK Investigational Site
Guimarães, Portugal, 4835-044
Actively Recruiting
76
GSK Investigational Site
Craiova Dolj, Dolj, Romania, 200535
Actively Recruiting
77
GSK Investigational Site
Cluj-Napoca, Romania, 400015
Actively Recruiting
78
GSK Investigational Site
Craiova, Romania, 200542
Actively Recruiting
79
GSK Investigational Site
Floreşti, Romania, 407280
Actively Recruiting
80
GSK Investigational Site
Iași, Romania, 700451
Actively Recruiting
81
GSK Investigational Site
Timișoara, Romania, 300329
Actively Recruiting
82
GSK Investigational Site
Changwon, South Korea, 51472
Actively Recruiting
83
GSK Investigational Site
Cheongju Chungcheongbuk-do, South Korea, 28644
Actively Recruiting
84
GSK Investigational Site
Daegu, South Korea, 41404
Actively Recruiting
85
GSK Investigational Site
Gyeonggi-do, South Korea, 10408
Actively Recruiting
86
GSK Investigational Site
Seongnam-si Gyeonggi-do, South Korea, 13620
Actively Recruiting
87
GSK Investigational Site
Seoul, South Korea, 03722
Actively Recruiting
88
GSK Investigational Site
Suwon Gyeonggi-do, South Korea, 442723
Actively Recruiting
89
GSK Investigational Site
Ulsan, South Korea, 44033
Actively Recruiting
90
GSK Investigational Site
Barcelona, Spain, 08035
Actively Recruiting
91
GSK Investigational Site
Barcelona, Spain, 8017
Actively Recruiting
92
GSK Investigational Site
Barcelona, Spain, 8036
Actively Recruiting
93
GSK Investigational Site
L'Hospitalet de Llobrega, Spain, 08908
Actively Recruiting
94
GSK Investigational Site
Las Palmas de Gran Canar, Spain, 35016
Actively Recruiting
95
GSK Investigational Site
Madrid, Spain, 28007
Actively Recruiting
96
GSK Investigational Site
Madrid, Spain, 28034
Actively Recruiting
97
GSK Investigational Site
Madrid, Spain, 28041
Actively Recruiting
98
GSK Investigational Site
Madrid, Spain, 28046
Actively Recruiting
99
GSK Investigational Site
Santander, Spain, 39011
Actively Recruiting
100
GSK Investigational Site
Stockholm, Sweden, 171 64
Actively Recruiting
101
GSK Investigational Site
Basel, Switzerland, 4031
Actively Recruiting
102
GSK Investigational Site
Lausanne, Switzerland, 1011
Actively Recruiting
103
GSK Investigational Site
Adana, Adana, Turkey (Türkiye), 01140
Actively Recruiting
104
GSK Investigational Site
Samsun, Atakum, Turkey (Türkiye), 55200
Actively Recruiting
105
GSK Investigational Site
Ankara, Turkey (Türkiye), 06010
Actively Recruiting
106
GSK Investigational Site
Ankara, Turkey (Türkiye), 06100
Actively Recruiting
107
GSK Investigational Site
Ankara, Turkey (Türkiye), 06520
Actively Recruiting
108
GSK Investigational Site
Diyarbakır, Turkey (Türkiye), 21280
Actively Recruiting
109
GSK Investigational Site
Istanbul, Turkey (Türkiye), 34010
Actively Recruiting
110
GSK Investigational Site
Izmir, Turkey (Türkiye), 35110
Actively Recruiting
111
GSK Investigational Site
Izmir, Turkey (Türkiye), 35340
Actively Recruiting
112
GSK Investigational Site
London, United Kingdom, W1G 6AD
Actively Recruiting
113
GSK Investigational Site
Portsmouth, United Kingdom, PO6 3LY
Actively Recruiting
114
GSK Investigational Site
Truro, United Kingdom, TR1 3LJ
Actively Recruiting
Research Team
U
US GSK Clinical Trials Call Center
CONTACT
E
EU GSK Clinical Trials Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here